Feed excerpt — reported by MarketWatch
The controversial investor has been weighing in on biopharma stocks even though he’s banned from doing so.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at MarketWatch →